Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy
Status:
Recruiting
Trial end date:
2033-12-28
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, open label, phase III study comparing the efficacy and
safety of apatulamide combined with concomitant prostate-bed salvage radiotherapy (SRT) and
androgen deprivation therapy (ADT) versus concomitant prostate-bed SRT and ADT in high-risk
postprostatectomy biochemically relapsed prostate cancer patients.